Understand the source comparison
SS-LUP-332 FDA Approved Status: Research-Grade Compound Comparison
SS-LUP-332 Investigational—no IND filed Pre-Phase I (no clinical trials initiated) In vitro mitochondrial studies, preclinical AMPK pathway research Requires institutional affiliation, PI signature, IACUC or IRB documentation for animal/in vitro work Mechanist
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332
- Investigational—no IND filed
- Pre-Phase I (no clinical trials initiated)
- In vitro mitochondrial studies, preclinical AMPK pathway research
- Requires institutional affiliation, PI signature, IACUC or IRB documentation for animal/in vitro work
- Mechanistically interesting but years from human use—appropriate for exploratory research only, not therapeutic development
- Semaglutide
- FDA-approved pharmaceutical
- Approved 2017 (Ozempic), 2021 (Wegovy)
- Clinical research under approved protocols; compounded versions available through 503B pharmacies during shortages
- Prescription required for approved formulations; compounded versions require licensed prescriber
- Established safety profile with extensive Phase III data—research-grade versions widely available but regulated as pharmaceuticals
- NMN (Nicotinamide Mononucleotide)
- Dietary supplement (FDA removed from supplement market 2022 pending drug investigation)
- Under FDA review as investigational drug following IND filing by Metro International Biotech
- NAD+ precursor studies, aging research, metabolic function
- Available as research-grade reagent; no therapeutic claims permitted
- Regulatory uncertainty—previously sold as supplement, now reclassified pending drug approval process
- Rapamycin
- FDA-approved pharmaceutical (immunosuppressant)
- Approved 1999 for organ transplant rejection
- Off-label aging research, mTOR inhibition studies, longevity protocols
- Prescription required; research-grade available through chemical suppliers with institutional documentation
- Approved drug with decades of safety data—repurposed for aging research but carries immunosuppression risks